Regeneron Reports Results from P-II (ROXI-VTE-I and ROXI-VTE-II) Trials of REGN7508 and REGN9933 for Venous Thromboembolism
Shots:
- The P-II (ROXI-VTE-I) study assessed REGN9933 (IV) vs enoxaparin (QD) & apixaban (BID) while ROXI-VTE-II evaluated REGN7508 (IV) vs enoxaparin (QD) for symptomatic/asymptomatic VTE prevention post TKA. Treatments began 12-24hrs. post-surgery
- Pooled analysis depicted VTE events in 7% with REGN7508 & 17% with REGN9933 vs 21% with enoxaparin & 12% with apixaban. REGN7508 was superior to enoxaparin & non-inferior to apixaban, while REGN9933 was non-inferior to enoxaparin in VTE rates
- No major or clinically relevant bleeding occurred across any arm, with 1 minor bleeding case (contusion) with enoxaparin in ROXI-VTE-I study. P-III trials will begin in 2025
Ref: Regeneron | Image: Regeneron
Related News:- Regeneron Reports Data from P-III (QUASAR) Trial of Eylea HD (Aflibercept) in Patients with Macular Edema following Retinal Vein Occlusion
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
